News | August 31, 2022
Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
The unit has filed 2 Derma products and 1 MDI product.
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
There are no data integrity (DI) observations.
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
Subscribe To Our Newsletter & Stay Updated
